Victoria Simms, PhD
Victoria Simms is a scientific writer with expertise in biotechnology, residing in Cheshire, UK.
12+ years experience interpreting medical research and data to produce educational and technical material for clinical trials, scientific research projects, international conferences, academic lectures, and community engagement events.
- PhD, Oncology and Cancer Biology, University of Birmingham, UK
- MSc, Biomedical Imaging, University of Birmingham, UK
- BSc, Biochemistry, University of York, UK
- Principles of Health & Medical Copywriting
To improve bladder cancer management for both patients and clinicians, Nonacus developed and launched GALEAS Bladder. This urine-based molecular biomarker test is highly accurate and sensitive at detecting all stages and grades of bladder cancer. It provides a simple sample-to-report, molecular triage for patients with hematuria; streamlining the clinical diagnosis process and reducing the need for cystoscopies.
To consolidate multiple testing strategies for haematological malignancies, our customer designed the first Nonacus NGS panel for both myeloid and lymphoid neoplasia
To help consolidate multiple testing strategies for haematological malignancies, our customer designed a Nonacus NGS panel, creating the first NGS workflow for both myeloid and lymphoid neoplasia.
Copy number variants are responsible for 5-10% of genetic disease – that’s why detecting them reliably and robustly is so important in clinical labs. Next Generation Sequencing panels have proven to be extremely useful for clinical applications and can successfully detect many genomic variants, but they can often struggle with CNV detection.
Tumor Mutational Burden has been highlighted as a reliable predictor of immunotherapy response across multiple cancer types offering the potential to help guide treatment decisions for cancer patients. Typically whole exome and genome sequencing are used to assess TMB but NGS panels offer a far more cost-effective method making them a more feasible option for routine clinical use.
Targeted NGS focuses sequencing efforts on specific subsets of the genome. By concentrating on certain genomic regions, it is possible to achieve greater sensitivity and robust calling of low frequency variants.
GALEAS® Bladder is a novel bladder cancer test providing a non-invasive, sample-to-report, molecular triage for patients with hematuria. The urine-based molecular biomarker, provides a highly sensitive test that can quickly and accurately detect bladder cancer and streamline diagnosis, thereby reducing the need for invasive cystoscopies.
A successful NGS assay using cell-free DNA (cfDNA) relies heavily on the pre-analytical steps of liquid biopsy collection, plasma preparation and cfDNA extraction.
Nonacus has developed an intuitive, online tool that allows you to create custom NGS panels with high on-target rates and uniform coverage – first time! This blog covers 5 tips to help you design a custom panel within minutes.
Nonacus ranked third fastest growing technology company in the UK in the Deloitte Technology Fast 50
Nonacus has been ranked within the top three fastest growing tech companies in the U.K, and first in healthcare, at the prestigious 2022 Deloitte Tech Fast 50 awards.